ENTO — Entero Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.73m
- $1.57m
- 10
- 59
- 27
- 23
Annual income statement for Entero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 26.8 | 59.1 | 12.7 | 15.8 | 15.6 |
| Operating Profit | -26.8 | -59.1 | -12.7 | -15.8 | -15.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32.7 | -58.5 | -14.6 | -15.8 | -15.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.7 | -58.5 | -14.6 | -15.8 | -15.6 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -32.7 | -58.5 | -14.6 | -15.8 | -18.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -41.7 | -84.5 | -15 | -16.1 | -18.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -61,054 | -38,667 | -417 | -47.9 | -4.62 |